BSI-082

N/A

Report date: 2025/12/08 11:24:30

Base Information

Drug NameBSI-082
Drug Alias NameBSI-082
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSignal-regulatory protein alpha inhibitors
TargetsSignal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiosion Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBiosion IncBiosin USA Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A